Iingxaki ze-IBD zingabandakanya i-Genetics kunye neNgqongileyo
Iingcali zenzululwazi aziqinisekanga oko kubangela ukuba izifo zesifo se-inflammatory disease (IBD) , esinezilonda zesilonda, isifo sikaCrohn, kunye nesifo soqhenqa. Kuthathwa njengesifo "idiopathic", okanye isifo esingaziwayo. Nangona kunjalo, kukho iingcamango ezininzi malunga nemvelaphi ye-IBD, kwakunye neemeko ezingabangela ukuba uphuhliso.
Asisazi kakuhle oko kubangele i-IBD, nangona kunjalo, sinemikhankaso ethile, kunye neengcamango ezininzi. Ngokuqhelekileyo kucatshangelwa ukuba kukho inxalenye yemfuza kwi-IBD, kwaye into ethile (okanye ngaphezulu kweyodwa into) kwimeko yethu ichaphazela iizakhi ezinxulumene ne-IBD. Oku kunokuthi "kubangele" i-IBD, kwaye ube ngowokuqala kweempawu. Ngoxa abaphandi bafunde ezininzi malunga namajethi anokunxulumana ne-IBD, yinto engundoqo yokunqongophala. Kuye kucatshangelwa ukuba kukho iininzi zeentlobo ezahlukeneyo ze-IBD, nangona sisazibandakanya kwiindidi ezi-3 ukuze zibaphathe ngamachiza. Kukho, ngokwenene, nokuba ngamakhulu okanye amawaka okubangela. Olunye uphando lubhekiselele kumathuba athile ngenxa yesizathu sokuba abanye abantu abaneengqungquthela ze-IBD bavelise i-IBD kunye nabanye abantu abakwenziyo.
Genetics kunye ne-IBD
Kwiminyaka edlulileyo, kwakucatshangelwa ukuba i-IBD ingabaleka kwiintsapho, kodwa ikhonkco yayibonakala ingenangqondo kuba yayingeyona imeko ngqo yomzali, kumzekelo, kunye neemeko ezithile ezizuze njengefa.
Ngokufunyanwa kwamaninzi amajethi angabandakanywa ne-IBD, kubonakala ukuba kukho inxalenye yefa kwi-IBD. Izalamane zokuqala zabantu abane-IBD banako ukufumana isifo. Nangona kunjalo, uninzi lwabantu abane-IBD abanalo imbali yentsapho , ngoko ke akuyena wonke umntu unelungu lentsapho elinesifo.
Ngoko ngelixa i-IBD isebenza ngokucacileyo kwiintsapho, akuyena kuphela umbandela onokuqwalaselwa xa ukhangela izizathu ezinokwenzeka ze-IBD. Kufuneka kubekho enye into eyenza abantu abathile banezifo ezifanayo kunye ne-IBD, ngelixa abanye bengenalo.
Impendulo ye-IBD yokuvusela
I-IBD ibizwa ngokuba yi- autoimmune isifo , isifo esibangelwa sisistim somzimba, kodwa kuchaneke ngakumbi ukuthetha ukuba yimpendulo yomzimba. Ukutshatyalaliswa kwexesha -kunyuka kwentwasahlobo okanye ekwindla-ngamanye amaxesha kwenzeka kubantu abane-IBD. Enye inkolelo kukuba le ngu- IgE-mediated response response .
Impendulo ye-allergen icwangcisa ukhenketho lweziganeko ezibangelwa kukugqithisa kwama- eosinophil (iiseli ezama ukulwa nokuphendula okuthe tye) emzimbeni. Ezi i-eosinophil zikhulula izixube ezine ezineetyhefu, ezintathu zazo zifumaneka kwiimali ezibalulekayo kwisigxina sezilwanyana ze-IBD. Oku kubangela ukuba abanye baphandi baphethe ngokuthi impendulo yokugula ingabandakanyeka ekuphuhlisweni kwe-IBD.
IiCytokines
Omnye ummandla oqinileyo wophando yiyona indima ama- cytokines adlala ngayo ekuphuhlisweni kwe-IBD. Iiseli ezibizwa ngokuba yi-tumor necrosis factor (TNF, okanye ngamanye amaxesha kuthiwa i-tumor necrosis factor-alpha) ixanduva lokulawula ukuphendula komzimba, phakathi kwezinye izinto.
I-TNF ifumaneka kwizinto eziphezulu kwisigxina sabantu abane-IBD kunabantu abangenayo i-IBD (nge-test fecal calprotectin). Ukuqala ngokuvunyelwa kwe-Remicade ngo-1998, iziyobisi ezininzi ze-TNF (ezibizwa ngokuba yi-biologics) ziye zaphuhliswa ukuphatha i-IBD. Impumelelo yale myeza inika ubunzima emva kwengcamango yokuba i-TNF idlala indima ethile kwi-IBD okanye ukuvuvukala okunxulumene ne-IBD flare-ups.
Izinto zeNdalo kwi-IBD
Kukho iindlela ezicacileyo kwi- epidemiology ye-IBD engayichazela enye okanye izizathu ezingqongileyo. I-IBD ijwayele ukuvela kwiindawo eziphuhlisiweyo kumazwe athuthukileyo kunye nakwabo abanezinga eliphezulu lezepolonomi.
I-IBD ibuye iqhube ngokuphindaphindiweyo kwiindawo ezisemaphandleni kumazwe athuthukileyo. Ezi zinto ziholele abaphandi ukuba bacinge ukuba kukho ukuxhamla phakathi kwe-IBD kunye nendlela yokuphila okanye imeko yabantu abahlala kumazwe athuthukileyo, nangona kungekho mntu owaziyo okwenzekayo.
Omnye ucetyiswa ukuba iindwendwe ezithengiweyo "zihlambulukile" , kwaye ngenxa yokuba abantwana nabantwana abaselula bayabonakala kwiibhaktheriya ezimbalwa, amasosha abo omzimba angasenelanga, okukhokelela kwisifo sokuzimela.
Inqaku esuka
Asiyazi kakuhle oko kubangela i-IBD, kodwa siyazi ukuba akubangelwa kukutya okanye uxinzelelo. Kukho ngokucacileyo i-genetic component eqhuba kwiintsapho, kodwa yile nxalenye yesibini, into ejikeleze kuthi "ishukumisa" izakhi zofuzo ezinzima ukuzifumana. Iindaba ezilungileyo kukuba sisazi ngakumbi ngoku ngoku malunga ne-IBD kunokuba sasineminyaka elishumi nje edlulileyo. Uphando olungakumbi luyenziwa, kwaye izazinzulu zisondela kwaye zisondele ekuqondeni indlela esinokuphatha ngayo ezi zifo ngokufanelekileyo nangokuzikhusela kwizizukulwana ezizayo.
Imithombo:
Bernstein CN, Fried M, Krabshuis JH, et al. "I-World Gastroenterology Organisation Practice Guidelines for Diagnosis and Management of IBD ngo-2010." I-Inflamm Bowell Dis 2010; 16: 112-124.
Crohn's and Colitis Foundation of America. "Nge-Epidemiology ye-IBD." CCFA.org 2009.
Isizwe seSizwe soSifo sikashukela kunye neeNtsholongwane zeNtsholongwane. "Ulcerative Colitis." Iziko zeSizwe zezeMpilo ngoFebruwari 2006.
Peterson CG, Sangfelt P, Wagner M, Hansson T, Lettejö H, Carlson M. "Amanqanaba amaFecal of markers leukocyte abonisa umsebenzi wesifo kwizigulane ezinezilonda zesilonda." I-Scand J Clin Lab Invest 2007; 67: 810-820.
Saitoh O, Kojima K, Sugi K, Matsuse R, et al. "Ama-protein ase-Fecal eosinophil-derived protein aveza umsebenzi wesifo kwisifo sofuba." InguJ Gastroenterol 1999 Dec; 94: 3513-3520.
Stensen WF, Snapper SB. " Umngeni kwi-IBD Research: UkuHlola iNqubekela phambili kunye nokuHlaziya iNkqubo yoPhando ." Ngomhla we-Bowel Dis 2008; 14: 687-708.